Építés alatt – nem éles oldal
Belépés
Visszavonva2. fázis

Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis

A legfontosabb adatok

Ki végzi
Stanford University
Hol
Stanford (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Visszavonva
Fázis
2. fázis
Kezdés
2030. dec. 1.
Várható befejezés
2030. dec.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Ivermectin Pill
A regiszteradat frissítve
2024. december 2.
Miért állt le
Limited clinical capacity

Ki vehet részt

Életkor
18 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 23 feltétel megnézéseKevesebb

Ki vehet részt

  • Must have at least one lesion of atopic dermatitis (At least 1% Body surface Area)
  • 18 years of age or older
  • Must be willing to take oral ivermectin once weekly for 4 weeks and monitor over 8 weeks
  • For women of child bearing potential, a negative urine pregnancy test
  • Women of child bearing potential are expected to use an effective method of birth control while participating in the study and for 1 month after taking the last dose
  • For male subjects with female partners of childbearing potential, agreement to use adequate contraception while participating in the study and for 1 month after taking the last dose
  • Has signed and dated the current Institutional Review Board approved informed consent document
  • Must be able to read and speak English fluently

Ki nem vehet részt

  • Has had known or previous hypersensitivity or allergic reactions to oral ivermectin before
  • Taking any medication known to interact with ivermectin like Dasabuvir (theoretical) or warfarin (probable)
  • Has an immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus rheumatoid arthritis) which could place the subject at risk or interfere with the accuracy of the study results
  • Has a history of hypersensitivity to any substance in investigational preparation
  • Has other skin conditions that might interfere with Atopic Dermatitis diagnosis and/or evaluation (i.e. psoriasis current active viral, bacterial and fungal skin infections) as assessed by the Investigator
  • Any other condition or factor the Investigator or their duly assigned representative believes may affect the ability of the subject to complete the study or the interpretation
  • History of congestive heart failure; cardiac arrhythmias; or other findings of ventricular dysfunction
  • History of current evidence of malabsorption or liver disease
  • Has any clinically significant medical condition or laboratory abnormality that would, in the opinion of the Investigator, put the patient at undue risk or interfere with the interpretation of the study results
  • Is age <18 years old
  • Is currently participating or has participated in another interventional clinical study in the past 2 weeks
  • Is planning a trip to a sunny climate, to use tanning booths or use other UV sources throughout the course of this study
  • Is currently pregnant or breastfeeding
  • Cannot read and speak English fluently
  • Does not have at least 1% body surface area with lesional atopic dermatitis

Helyszínek itt: Egyesült Államok

  • Stanford Hospital and ClinicsStanford, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This pilot trial studies how well a novel oral therapeutic agent performs to treat patients with atopic dermatitis, particularly facial dermatitis.

A vizsgálat csoportja

  • Oral treatmentA vizsgált kezelés

    12mg oral ivermectin treatment taken once a week for four weeks

    Kezelés: Ivermectin Pill

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2024. december 2.